RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease Aug 1, 2017 Life Science
WuXi AppTec Merges Formulation/Finishing Services into API Manufacturing Division Jul 31, 2017 Life Science
CSPC Pharma Signs $118.5 Million Deal for Two Molecules from University of Texas Jul 27, 2017 Life Science
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial Jul 26, 2017 Life Science
Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017 Jul 26, 2017 Life Science
